{"id":"NCT02127970","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","briefTitle":"Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","officialTitle":"A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04-18","primaryCompletion":"2015-03-11","completion":"2015-03-11","firstPosted":"2014-05-01","resultsPosted":"2018-08-14","lastUpdate":"2018-09-28"},"enrollment":698,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Abscess","Wound Infection","Surgical Site Infection","Cellulitis"],"interventions":[{"type":"DRUG","name":"Dalbavancin","otherNames":["DALVANCEÂ®"]},{"type":"DRUG","name":"Dalbavancin-matching Placebo","otherNames":[]}],"arms":[{"label":"Single-Dose Dalbavancin","type":"EXPERIMENTAL"},{"label":"Two-Dose Dalbavancin","type":"EXPERIMENTAL"}],"summary":"To compare the efficacy of treatment with a single dose of dalbavancin 1500 mg to treatment with a two dose regimen of dalbavancin (1000 mg on Day 1 followed by 500 mg on Day 8) in participants with known or suspected Gram-positive acute bacterial skin and skin structure infections (ABSSSI) at 48 -72 hours after initiation of treatment.","primaryOutcome":{"measure":"Percentage of Participants Who Were Clinical Responders 48-72 Hours After the Initiation of Study Drug","timeFrame":"Up to 48-72 hours after the initiation of study drug","effectByArm":[{"arm":"Single-Dose Dalbavancin","deltaMin":81.4,"sd":null},{"arm":"Two-Dose Dalbavancin","deltaMin":84.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":27},"locations":{"siteCount":78,"countries":["United States","Bulgaria","Croatia","Estonia","Georgia","Hungary","Latvia","Romania","Russia","Serbia","South Africa","Ukraine"]},"refs":{"pmids":["34905144","30797084","26611777"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":349},"commonTop":[]}}